Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments
Sanara MedTech (NASDAQ: SMTI) has announced key changes to its executive leadership team effective January 15, 2025. Elizabeth Taylor has been appointed as Chief Financial Officer, succeeding Michael McNeil, who transitions to the roles of Chief Accounting Officer and Chief Administrative Officer.
Taylor brings over 25 years of financial experience, including previous positions as CFO at Imbed Biosciences, COO of multiple hedge funds, and investment team member at a private equity firm. She most recently served as CFO at Imbed Biosciences from 2023 to 2025, where she managed budgeting, forecasting, and financial analysis. Her background includes founding Burnett Taylor Consulting, serving as COO at PioneerPath Capital and Tala Investments, and working at Thomas H. Lee Partners.
Ron Nixon, Sanara's Executive Chairman and CEO, emphasized that Taylor's combination of industry and Wall Street experience will complement their existing finance and accounting teams as they continue their growth phase in the surgical, chronic wound, and skincare markets.
Sanara MedTech (NASDAQ: SMTI) ha annunciato importanti cambiamenti nel suo team dirigenziale a partire dal 15 gennaio 2025. Elizabeth Taylor è stata nominata Chief Financial Officer, succedendo a Michael McNeil, che assumerà i ruoli di Chief Accounting Officer e Chief Administrative Officer.
Taylor porta con sé oltre 25 anni di esperienza finanziaria, avendo ricoperto precedenti posizioni come CFO presso Imbed Biosciences, COO in vari hedge fund e membro del team di investimento in una società di private equity. Recentemente, ha ricoperto il ruolo di CFO presso Imbed Biosciences dal 2023 al 2025, dove si è occupata della pianificazione, delle previsioni e dell'analisi finanziaria. Il suo curriculum include la fondazione di Burnett Taylor Consulting, il servizio come COO presso PioneerPath Capital e Tala Investments, e l'esperienza presso Thomas H. Lee Partners.
Ron Nixon, Presidente Esecutivo e CEO di Sanara, ha sottolineato che la combinazione di esperienza nel settore e a Wall Street di Taylor completerà i loro attuali team finanziari e contabili, mentre continuano la loro fase di crescita nei mercati chirurgici, delle ferite croniche e della cura della pelle.
Sanara MedTech (NASDAQ: SMTI) ha anunciado cambios clave en su equipo de liderazgo ejecutivo a partir del 15 de enero de 2025. Elizabeth Taylor ha sido nombrada Directora Financiera, sucediendo a Michael McNeil, quien pasará a desempeñar los roles de Director de Contabilidad y Director Administrativo.
Taylor aporta más de 25 años de experiencia financiera, incluidos puestos anteriores como CFO en Imbed Biosciences, COO de múltiples fondos de cobertura y miembro del equipo de inversión en una firma de capital privado. Recientemente, se desempeñó como CFO en Imbed Biosciences desde 2023 hasta 2025, donde gestionó la elaboración de presupuestos, la previsión y el análisis financiero. Su trayectoria incluye la fundación de Burnett Taylor Consulting, su trabajo como COO en PioneerPath Capital y Tala Investments, y su labor en Thomas H. Lee Partners.
Ron Nixon, Presidente Ejecutivo y CEO de Sanara, destacó que la combinación de experiencia de Taylor en la industria y Wall Street complementará a sus equipos financieros y contables existentes mientras continúan su fase de crecimiento en los mercados quirúrgico, de heridas crónicas y de cuidado de la piel.
Sanara MedTech (NASDAQ: SMTI)는 2025년 1월 15일부로 경영진 리더십 팀의 주요 변화를 발표했습니다. 엘리자베스 테일러가 최고재무책임자(CFO)로 임명되었으며, 마이클 맥닐은 최고회계책임자(CAO) 및 최고행정책임자(CAO) 역할로 전환됩니다.
테일러는 25년 이상의 재무 경험을 갖추고 있으며, 이전에는 Imbed Biosciences의 CFO, 여러 해지펀드의 COO, 사모펀드의 투자팀 구성원으로 활동했습니다. 최근 2023년부터 2025년까지 Imbed Biosciences의 CFO로 재직하며 예산 수립, 예측 및 재무 분석을 담당했습니다. 그녀의 경력에는 Burnett Taylor Consulting의 설립, PioneerPath Capital 및 Tala Investments의 COO로 재직한 경험, Thomas H. Lee Partners에서의 근무 경험이 포함됩니다.
Ron Nixon, Sanara의 집행 회장 겸 CEO는 테일러의 업계 및 월스트리트 경험의 조합이 외과, 만성 상처 및 스킨케어 시장에서 성장 단계에 있는 기존의 재무 및 회계 팀을 보완할 것이라고 강조했습니다.
Sanara MedTech (NASDAQ: SMTI) a annoncé des changements clés dans son équipe de direction à compter du 15 janvier 2025. Elizabeth Taylor a été nommée Directrice financière, succédant à Michael McNeil, qui passera aux fonctions de Directeur comptable et Directeur administratif.
Taylor possède plus de 25 ans d'expérience dans le domaine financier, ayant précédemment occupé des postes de CFO chez Imbed Biosciences, COO de plusieurs fonds spéculatifs et membre d'une équipe d'investissement dans une société de capital-investissement. Elle a récemment été CFO chez Imbed Biosciences de 2023 à 2025, où elle était responsable de la budgétisation, des prévisions et de l'analyse financière. Son parcours comprend la fondation de Burnett Taylor Consulting, un poste de COO chez PioneerPath Capital et Tala Investments, ainsi qu'une expérience chez Thomas H. Lee Partners.
Ron Nixon, président exécutif et CEO de Sanara, a souligné que la combinaison de l'expérience de Taylor dans l'industrie et à Wall Street complétera leurs équipes financières et comptables existantes alors qu'ils poursuivent leur phase de croissance sur les marchés chirurgical, des plaies chroniques et des soins de la peau.
Sanara MedTech (NASDAQ: SMTI) hat wesentliche Änderungen in seinem Führungsteam zum 15. Januar 2025 angekündigt. Elizabeth Taylor wurde zur Chief Financial Officer ernannt und tritt damit die Nachfolge von Michael McNeil an, der in die Rollen des Chief Accounting Officer und Chief Administrative Officer wechselt.
Taylor bringt über 25 Jahre Erfahrung im Finanzbereich mit, darunter frühere Positionen als CFO bei Imbed Biosciences, COO mehrerer Hedgefonds und Mitglied eines Investmentteams in einer Private-Equity-Firma. Zuletzt war sie von 2023 bis 2025 CFO bei Imbed Biosciences, wo sie für Budgetierung, Prognosen und Finanzanalysen verantwortlich war. Ihr Werdegang umfasst die Gründung von Burnett Taylor Consulting, die Tätigkeit als COO bei PioneerPath Capital und Tala Investments sowie die Arbeit bei Thomas H. Lee Partners.
Ron Nixon, Executive Chairman und CEO von Sanara, betonte, dass Taylors Kombination aus Branchen- und Wall-Street-Erfahrung die bestehenden Finanz- und Buchhaltungsteams ergänzen wird, während sie weiterhin in den Märkten für chirurgische Eingriffe, chronische Wunden und Hautpflege wachsen.
- Appointment of CFO with extensive medical device industry experience
- New CFO brings diverse financial background including hedge fund and private equity expertise
- Internal promotion of existing CFO to maintain continuity in financial operations
- Strategic leadership expansion to support company growth phase
- None.
Elizabeth Taylor Appointed Chief Financial Officer;
Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer
FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company’s executive leadership team with new appointments.
Elizabeth Taylor has been appointed to the position of Chief Financial Officer. Ms. Taylor succeeds Michael McNeil, who has been appointed to serve as Chief Accounting Officer and Chief Administrative Officer. The appointments were effective as of January 15, 2025.
“We are pleased to expand our leadership team with these key appointments,” stated Ron Nixon, Sanara’s Executive Chairman and CEO. “Elizabeth possesses over 25 years of financial experience, with a career history that includes prior positions as Chief Financial Officer of a medical device company focused on the treatment of wounds, Chief Operating Officer of multiple hedge funds, and as a member of the investment team at a leading private equity firm. Her combination of industry and Wall Street experience will complement the strengths of our existing finance and accounting teams, building upon the outstanding accomplishments made by Mike McNeil, who will lead financial reporting and accounting policy as Chief Accounting Officer and Chief Administrative Officer. We welcome Elizabeth to Sanara and look forward to leveraging her expertise and insight as we continue our next phase of growth and development as an organization.”
“Sanara has established an impressive track record of sales performance and operational progress over the past five years, and remains well-positioned in the market with multiple opportunities to drive strong, sustained growth going forward,” stated Elizabeth Taylor, Sanara’s CFO. “I am excited to join the Company during this important stage in its development, and look forward to contributing to its future success as we continue to penetrate our large addressable market opportunity in the surgical, chronic wound and skincare markets.”
Ms. Taylor joins Sanara from Imbed Biosciences, a privately held medical device company developing and commercializing innovative solutions to improve wound care. She served as its Chief Financial Officer from 2023 to 2025, where she was responsible for budgeting, forecasting and financial analysis, and as a member of its board of directors from 2018 to 2023. Beginning in 2011, Ms. Taylor previously worked as an umbrella financial advisor for family offices and high-net worth clients at Burnett Taylor Consulting, LLC, which she founded and managed.
From 2008 to 2010, Ms. Taylor served as Chief Operating Officer of PioneerPath Capital, an alternative asset manager and incubation platform within Citadel, a global investment firm. Ms. Taylor was responsible for the platform’s launch and business management, including overseeing all internal accounting, budgeting and management reporting functions. She was Chief Operating Officer of Tala Investments, L.P., a value-focused hedge fund, from 2005 to 2008. Prior to Tala Investments, Ms. Taylor worked for Thomas H. Lee Partners, L.P. (THL), a private equity firm focused on investing in middle-market growth companies, joining the firm as an investment analyst for the firm’s
Ms. Taylor holds an M.B.A. from Harvard Business School and a B.A. from Princeton University.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. For more information, please visit sanaramedtech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, the regulatory approval process and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as the Company’s ability to attract and retain key employees, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by, these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
When did Elizabeth Taylor join Sanara MedTech (SMTI) as CFO?
What is Elizabeth Taylor's previous experience before joining SMTI?
What is Michael McNeil's new role at Sanara MedTech (SMTI)?
What markets does Sanara MedTech (SMTI) operate in?
